BIIB vs. JNJ: Biogen vs. Johnson & Johnson Stock Comparison
This page compares Biogen (BIIB) with Johnson & Johnson (JNJ) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Performance
Cumulative Growth
Trailing Returns
Performance at a Glance
| Metric | BIIB | JNJ |
|---|---|---|
| 1-Year Return | 51.20% | 57.60% |
Risk
Drawdown
Risk at a Glance
| Metric | BIIB | JNJ |
|---|---|---|
| 1-Year Volatility | 33.53% | 16.96% |
| Beta | 0.17 | 0.25 |
| 3-Month Avg. Volume | 1.16M | 7.68M |
Company Profile
Biogen (BIIB) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while JNJ is classified in Pharmaceuticals.
| Profile Item | BIIB | JNJ |
|---|---|---|
| Name | Biogen Inc. | Johnson & Johnson |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 29.53 billion USD | 579.83 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | September 17, 1991 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Both Biogen (BIIB) at 21.51 and Johnson & Johnson (JNJ) at 27.94 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.51
- Max
- 77.14
- Q3
- 43.78
- Median
- 24.68
- BIIB
- 21.51
- Q1
- 15.27
- Min
- 1.70
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.94
- Max
- 77.14
- Q3
- 43.78
- JNJ
- 27.94
- Median
- 24.68
- Q1
- 15.27
- Min
- 1.70
Price-to-Sales Ratio (TTM)
Biogen (BIIB) at 2.97 sits in the cheaper P/S ratio quartile while Johnson & Johnson (JNJ) at 6.02 prices around its industry’s middle — BIIB costs less per dollar of sales, though read it alongside growth and margins.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 55.38
- Q3
- 24.42
- Median
- 6.98
- Q1
- 3.30
- BIIB
- 2.97
- Min
- 0.01
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.02
- Max
- 55.38
- Q3
- 24.42
- Median
- 6.98
- JNJ
- 6.02
- Q1
- 3.30
- Min
- 0.01
Price-to-Book Ratio (MRQ)
Biogen (BIIB) at 1.58 looks cheap against book in the lower P/B ratio quartile, while Johnson & Johnson (JNJ) at 7.14 carries a premium in the upper quartile — a clear price-to-book gap.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 13.23
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- BIIB
- 1.58
- Min
- -5.17
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.14
- Max
- 13.23
- JNJ
- 7.14
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- Min
- -5.17
Valuation at a Glance
| Metric | BIIB | JNJ |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 21.51 | 27.94 |
| Price-to-Sales Ratio (TTM) | 2.97 | 6.02 |
| Price-to-Book Ratio (MRQ) | 1.58 | 7.14 |
| Free Cash Flow Yield | 6.54% | 2.16% |
Profitability
Return on Equity (TTM)
Both Biogen (BIIB) at 7.70% and Johnson & Johnson (JNJ) at 26.42% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.70%
- Max
- 101.32%
- BIIB
- 7.70%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.42%
- Max
- 101.32%
- JNJ
- 26.42%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
Net Profit Margin (TTM)
Both Biogen (BIIB) at 13.81% and Johnson & Johnson (JNJ) at 21.83% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.81%
- BIIB
- 13.81%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.83%
- JNJ
- 21.83%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
Operating Profit Margin (TTM)
Both Biogen (BIIB) at 22.90% and Johnson & Johnson (JNJ) at 27.41% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.90%
- Max
- 100.30%
- BIIB
- 22.90%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.41%
- Max
- 100.30%
- JNJ
- 27.41%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
Profitability at a Glance
| Metric | BIIB | JNJ |
|---|---|---|
| Return on Equity (TTM) | 7.70% | 26.42% |
| Return on Assets (TTM) | 5.95% | 8.42% |
| Net Profit Margin (TTM) | 13.81% | 21.83% |
| Operating Profit Margin (TTM) | 22.90% | 27.41% |
| Gross Profit Margin (TTM) | 78.72% | 68.04% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Metric | BIIB | JNJ |
|---|---|---|
| 1-Year Revenue Growth | 2.22% | 6.05% |
| 3-Year Revenue CAGR | -0.94% | 5.60% |
EPS Growth
EPS Growth at a Glance
| Metric | BIIB | JNJ |
|---|---|---|
| 1-Year EPS Growth | -21.38% | 90.50% |
| 3-Year EPS CAGR | -25.04% | 17.90% |
Financial Strength
Current Ratio (MRQ)
Biogen (BIIB) at 3.07 keeps current ratio within its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.03 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JNJ.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.07
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- BIIB
- 3.07
- Q1
- 2.69
- Min
- 0.23
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.03
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- Q1
- 2.69
- JNJ
- 1.03
- Min
- 0.23
Debt-to-Equity Ratio (MRQ)
Both Biogen (BIIB) at 0.35 and Johnson & Johnson (JNJ) at 0.68 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.60
- Q3
- 0.68
- BIIB
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.68
- Max
- 1.60
- Q3
- 0.68
- JNJ
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength at a Glance
| Metric | BIIB | JNJ |
|---|---|---|
| Current Ratio (MRQ) | 3.07 | 1.03 |
| Debt-to-Equity Ratio (MRQ) | 0.35 | 0.68 |
| Net Debt / EBITDA | 0.64 | 0.96 |
Dividends
Dividend Yield (TTM)
Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 2.23%, ranking against industry peers normally.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.23%
- JNJ
- 2.23%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Biogen (BIIB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 60.25%, ranking against industry peers normally.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
60.25%
- JNJ
- 60.25%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Metric | BIIB | JNJ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.23% |
| Dividend Payout Ratio (TTM) | 0.00% | 60.25% |